Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
347
resultados
Última actualización
27/07/2026 [09:40:00]
Resultados 225 a 250 de 347
Resumen de: CN122214280A
本发明涉及一种分泌维生素B3单克隆抗体的杂交瘤细胞株及其应用，属于免疫检测技术领域。本发明经过多次筛选获得了一种能够分泌维生素B3单克隆抗体的杂交瘤细胞株，本发明的杂交瘤细胞株分泌的维生素B3单克隆抗体对维生素B3具有优异的亲和力和灵敏度，对维生素B3的IC50达到14.36 ng/mL，且对于维生素B3的结构类似物，例如维生素A、维生素K2、维生素K3、维生素K4、维生素E均无交叉反应。因此本发明的单克隆抗体可用于制备维生素B3的免疫检测产品，为维生素B3的残留检测提供高效的检测方法及手段。
Resumen de: CN122193589A
0001 本发明提供了一种阿尔茨海默症患者尿液中的相关性蛋白检测方法及其应用，涉及生物医药领域，检测方法包括：取预制有荧光微球标记的蛋白抗体2和磁颗粒标记的蛋白抗体1的反应管；将尿液样本加入到反应管中；向反应管中加入尿液稀释液，混匀后室温放置，反应8‑12小时；使用磁铁富集免疫复合物，用紫光照射复合物，判断复合物荧光强度。通过利用一对配对的抗体（捕获抗体与检测抗体）特异性抓取尿液中的超低浓度靶蛋白，通过磁珠将其从复杂基质中拾取并浓缩，再借助高亮度荧光微球将生物识别事件转化为强烈的光信号，最终通过肉眼或仪器实现定性或定量检测，进而实现对尿液中相关性蛋白进行检测的目的，降低了操作门槛和经济成本。
Resumen de: CN122187963A
0001 本发明涉及一种靶向β‑淀粉样蛋白的纳米抗体及其应用。所述纳米抗体的CDR1的氨基酸序列包括SEQ ID NO.1或与SEQ ID NO.1具有至少80％同一性的序列，CDR2的氨基酸序列包括SEQ ID NO.2或与SEQ ID NO.2具有至少80％同一性的序列，CDR3的氨基酸序列包括SEQ ID NO.3或与SEQ ID NO.3具有至少80％同一性的序列。本发明设计制备全新的靶向β‑淀粉样蛋白的纳米抗体，能够靶向和结合多种形式Aβ蛋白，具备高亲和力，可有效应用于β‑淀粉样蛋白的检测以及AD的诊断和治疗等领域，同时具备合成成本低、性质稳定等优点，利于推广应用。
Resumen de: CN122188000A
0001 本发明提供一种262位点磷酸化的Tau蛋白、其制备方法与应用，属于生物工程技术领域，本发明提供的262位点磷酸化的Tau蛋白的制备方法，包括以下步骤：S1：合成SEQ ID No.1所示的多肽序列，SEQ ID No.1：KSKIGSTENLKHCC，其中，SEQ ID No.1的第六位氨基酸为磷酸化丝氨酸；S2：偶联Tau蛋白和SEQ ID No.1所示的多肽，反应后获得262位点磷酸化的Tau蛋白。通过本发明提供的制备方法，可以完全避免非特异性过度磷酸化的问题，同时，提供上述制备方法制得的262位点磷酸化的Tau蛋白具有较高的结合效率和稳定性。
Resumen de: CN122193590A
本申请涉及一种用于评估或诊断多系统萎缩患者的血液生物标志物及其用途。其中的血液生物标志物为α‑Syn、NfL中至少一种与C3的组合。通过该血液生物标志物，能够辅助多系统萎缩患者的早期诊断和连续监测，检测成本低、操作简单、检测速度快、创伤性小、可及性好，适合大多数患者使用，临床应用价值高。
Resumen de: WO2024249528A2
The present disclosure provides methods, compositions, systems, and kits for expressing a protein in a target cell.
Resumen de: CN122187969A
0001 本发明涉及一种神经生长因子特异性抗体及其制备方法用途。本发明提供的抗体可以特异性识别检测重组人神经生长因子突变体，不结合人神经生长因子前体蛋白和/或野生型人神经生长因子及其前体蛋白，在重组人神经生长因子突变体的检测中具有良好的应用前景。
Resumen de: CN122182748A
0001 本发明公开了GLO2及其在促进或抑制炎症或免疫应答中的应用。其中涉及GLO2的编码核酸、GLO2蛋白质或GLO2的促进剂在制备用于促进炎症或免疫应答的药物中的应用，GLO2的抑制剂在制备用于抑制炎症或免疫应答的药物中的应用，和GLO2的检测剂在制备用于筛选针对炎症或免疫应答的药物和/或疗法的试剂盒中的应用。
Resumen de: WO2025059487A2
The present disclosure provides cell penetrating agents comprising a cell internalization module and an antibody or antigen binding antibody fragment thereof that specifically binds to human beta amyloid and methods of using these cell penetrating agents to treat patients with beta amyloid related diseases, including Inclusion-body myositis (IBM).
Resumen de: WO2025101478A1
The presently claimed and described technology provides methods for detecting phosphorylated tau (p-tau)217 in a biological sample using an immunoassay analyzer.
Resumen de: US20260160759A1
0000 Provided herein are methods and systems for multiplex detection and/or measurement of biomarkers of a sample. The methods and systems can be used for rapid disease detection and/or monitoring, vaccine efficacy and immune response monitoring, therapeutic drug monitoring, and/or therapeutic safety and efficacy monitoring.
Resumen de: US20260159878A1
0000 Disclosed herein, inter alia, are compositions and methods of use thereof for interrogating a cell.
Resumen de: WO2026118345A1
The present invention provides a rapid, visual, simple, and low-cost immunochromatographic test kit for combined detection of amyloid beta 1-42, NfL, and UCH-L1. The test kit comprises an immunochromatographic test strip, the test strip comprising a sample pad, a conjugate pad, and a nitrocellulose membrane, the conjugate pad comprising microsphere-labeled anti-amyloid beta 1-42, NfL, and UCH-L1 antibody conjugates. Employing combined detection of three markers, amyloid beta 1-42, NfL, and UCH-L1, increases diagnostic accuracy for early detection of Alzheimer's disease and for neurological health.
Resumen de: US20260160752A1
0000 A method for co-compartmentalising a cyclic polypeptide with a polynucleotide encoding the cyclic polypeptide, comprising the steps of a) forming a compartment containing a polynucleotide encoding the cyclic polypeptide, b) expressing a polypeptide from the polynucleotide, and c) cyclising the polypeptide. Co-compartmentalised cyclic polypeptides and encoding polynucleotides. Libraries of co-compartmentalised cyclic polypeptide and encoding polynucleotide. Methods for screening libraries of co-compartmentalised cyclic polypeptide and encoding polynucleotide. Incorporation of non-canonical nucleic acids into such libraries.
Resumen de: US20260158104A1
The present invention provides methods of making engineered viral proteins and protein complexes that are useful as vaccine immunogens, engineered viral proteins and protein complexes made using such methods, and pharmaceutical compositions comprising such engineered viral proteins and protein complexes. Such engineered viral proteins and protein complexes may comprise one or more cross-links that stabilize the conformation of an antibody epitope, such as a quaternary neutralizing antibody, and may exhibit an enhanced ability to elicit a protective immune response when administered to a subject as a component of a vaccine.
Resumen de: US20260160769A1
0000 A detection device and associated systems and methods for detecting analytes from a multiplex reaction are described. In particular, a device for conducting at least one detection reaction using a modified ELISA method including a surface with a detection region and a reference region, a detection sensor, and a light source. The detection device may include a complementary metal-oxide-semiconductor (CMOS) image sensor. The device may be used to measure and report discrete quantities or combinations of discrete analytes, providing information to aid in the prognosis and/or diagnosis of altered states of health in vertebrates.
Resumen de: WO2026122090A1
Embodiments of the invention include a system and method of using biomarkers in the diagnosis of Alzheimer's disease. A subject can be screened for Alzheimer's disease based on altered expression of one or more biomarkers in blood, plasma or saliva from the subject. Embodiments include 43 specific mRNA biomarkers to screen or distinguish healthy individuals from individuals affected with Alzheimer's disease. The biomarkers can also be used to determine the prognosis of a subject with the disease and identify early-onset and/or asymptomatic Alzheimer's disease.
Resumen de: WO2026122927A1
Provided are methods for detecting or quantifying tau isoforms in a biological sample. The methods include detecting or quantifying big tau isoforms and small tau isoforms from a sample obtained from a subject. Also provided are methods for treating a subject identified as having or at risk for a neurological disorder based on tau isoforms detected or quantified from a sample from the subject.
Resumen de: WO2026122709A1
Provided herein are, inter alia, methods of inhibiting or reversing aging by inhibiting phosphorylation of eukaryotic translation initiation factor 4E (eIF4E). It is provided herewith that eIF4E protein stability and phosphorylation levels increase during aging and the methods of inhibition of eIF4E phosphorylation provided herein reverse symptoms and features of aging, extend lifespan, and reduce senescence.
Resumen de: WO2026120021A1
The present invention relates to a method for the diagnosis, the prognosis, for monitoring the evolution, or for determining the risk of having or developing neurodegenerative disease in a subject, or for determining the efficacy of a treatment of neurodegenerative disease in a subject. The method comprises detecting the presence of 3-hydroxy capric acid (10:0-3OH), 3-hydroxy lauric acid (12:0-3OH), 3-hydroxy myristic acid (14:0- 3OH), 3-hydroxy palmitic acid (16:0-3OH) and/or 3-hydroxy stearic acid (18:0-3OH) in a sample of biological fluid of said subject.
Resumen de: WO2026122610A1
Methods for making a reconstructed human brain tissue are provided. Also provided are methods for evaluating whether a drug candidate inhibits amyloid deposition.
Resumen de: WO2026118416A1
Provided are an antibody that targets a P-Tau181 protein, or an antigen-binding fragment thereof and the use thereof. The provided antibody can specifically recognize and bind to the P-Tau181 protein, and does not recognize p-Tau217 and non-phosphorylated Tau proteins, and therefore can be used for preparing detection formulations or kits for diagnosing p-Tau181 protein-related diseases, such as Alzheimer's disease.
Resumen de: US20260160682A1
0000 A method is for detecting a chemical messenger within a sample of blood. The method may include flowing the sample of blood over a sensing surface of a plasmonic array biosensor. The sensing surface of the plasmonic array biosensor may have an ssDNA aptamer against the chemical messenger. The method may further include binding the chemical messenger in the sample of blood to the ssDNA aptamer of the plasmonic array biosensor, and detecting the chemical messenger in the sample of blood based upon LSPR altering a reflected optical signal from the plasmonic array biosensor.
Resumen de: WO2026120847A1
The present invention addresses the problem of providing a method for detecting a protein contained in exosomes. The problem is solved by a method for detecting a protein contained in exosomes, the method including a step for subjecting a measurement sample that is an exosome-containing solution separated from a specimen to a proximity elongation assay (PEA) and quantifying a target protein in the sample.
Nº publicación: WO2026122584A1 11/06/2026
Solicitante:
WASHINGTON UNIVERSITY ST LOUIS [US]
WASHINGTON UNIVERSITY
Resumen de: WO2026122584A1
Antisense oligonucleotide strategies, including compositions and methods, for increasing protein levels are provided. Target proteins include but are not limited to tank binding protein kinase 1 (TBK-1 or TBK1), follistatin (FST), and progranulin (PGRN). The compositions and methods described herein are applicable for treatment of neurodegenerative diseases caused by haplo-insufficiency.
BOPI
Sede Electrónica
